← FDA DRUG APPROVALS

FDA ANDA · ANDA204228

OMEPRAZOLE AND SODIUM BICARBONATE

Sponsor: AJANTA PHARMA LTD

APPLICATION
ANDA204228
TYPE
ANDA
ORIGINAL APPROVAL
2016-07-15
LATEST ACTION
2023-11-15
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

OMEPRAZOLE AND SODIUM BICARBONATEPrescription
OMEPRAZOLE 20MG, SODIUM BICARBONATE 1.1GM · CAPSULE · ORAL
OMEPRAZOLE AND SODIUM BICARBONATEPrescription
OMEPRAZOLE 40MG, SODIUM BICARBONATE 1.1GM · CAPSULE · ORAL

Approval history

2023-11-15Labeling · Supplement 21 · standardAP
2023-11-15Labeling · Supplement 14 · standardAP
2023-11-15Labeling · Supplement 19 · standardAP
2020-02-24Labeling · Supplement 9 · standardAP
2020-02-24Labeling · Supplement 1 · standardAP
2020-02-24Labeling · Supplement 6 · standardAP
2016-07-15UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →